DB-1310 by Duality Biologics (Shanghai) for Solid Tumor: Likelihood of Approval
DB-1310 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData's report assesses how DB-1310's drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.DB-1310 overviewThe therapeutic candidates are under development for the treatment of metastatic solid tumor, non-small cell lung cancer, castration resistant prostate cancer and head and neck squamous cell cancer and HER2 positive breast cancer. The drug candidate is administered through intravenous route as injection. They are antibody drug conjugates (ADCs) developing based on duality immune toxin antibody conjugate platform.Duality Biologics (Shanghai) overviewDuality Biologics (Shanghai) is a company focusing on the development, commercialization and discovery of new modality biologics to provide solutions. The company is headquartered in Shanghai, China. For a complete picture of DB-1310's drug-specific PTSR and LoA scores, buy the report here.
DB-1310 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Solid Tumor.
What's Your Reaction?
